After leading teams and functions in biopharmaceutical product development in autoimmunity, inflammation, blood disorders, organ transplant rejection and the treatment of acute and chronic viral infections, I’m now charting a new path as an independent consultant leveraging my 25+ years of executive-level strategic experience in the pharma sector.
My career has allowed me to serve as the Chief Medical Officer of several companies, including Provention Bio (focused on intercepting and preventing autoimmune diseases), Global Blood Therapeutics (dedicated to developing novel therapeutics to treat blood-based disorders), Theraclone Sciences (a therapeutic antibody discovery and development company) and ZymoGenetics (focused on developing protein therapeutics).
During my career, I’ve led or played an important role in the development of several approved products: Provention Bio/Sanofi’s teplizumab/TZIELD®, Global Blood Therapeutics/Pfizer’s voxelotor/OXBRYTA®, Roche’s mycophenolate mofetil/CellCept® and daclizumab/Zenapax®; Bristol-Myers Squibb’s belatacept/NULOJIX®; and ZymoGenetics recombinant thrombin/RECOTHROM®.